Bbva Compass Bancshares Inc. reduced its stake in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 17.7% in the 4th quarter, Holdings Channel reports. The firm owned 11,138 shares of the biopharmaceutical company’s stock after selling 2,401 shares during the period. Bbva Compass Bancshares Inc.’s holdings in Regeneron Pharmaceuticals were worth $4,188,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors also recently made changes to their positions in the stock. Ark Investment Management LLC raised its position in Regeneron Pharmaceuticals by 78.8% during the 2nd quarter. Ark Investment Management LLC now owns 1,234 shares of the biopharmaceutical company’s stock worth $606,000 after buying an additional 544 shares during the last quarter. Fisher Asset Management LLC raised its position in Regeneron Pharmaceuticals by 11.6% during the 3rd quarter. Fisher Asset Management LLC now owns 1,574 shares of the biopharmaceutical company’s stock worth $704,000 after buying an additional 163 shares during the last quarter. APG Asset Management N.V. raised its position in Regeneron Pharmaceuticals by 11.1% during the 3rd quarter. APG Asset Management N.V. now owns 20,957 shares of the biopharmaceutical company’s stock worth $9,370,000 after buying an additional 2,100 shares during the last quarter. State of New Jersey Common Pension Fund D purchased a new position in Regeneron Pharmaceuticals during the 3rd quarter worth approximately $1,341,000. Finally, Calamos Wealth Management LLC purchased a new position in Regeneron Pharmaceuticals during the 3rd quarter worth approximately $668,000. 64.67% of the stock is owned by hedge funds and other institutional investors.
In related news, Director Joseph L. Goldstein sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, February 9th. The shares were sold at an average price of $325.60, for a total value of $325,600.00. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 10.80% of the stock is currently owned by company insiders.
Shares of Regeneron Pharmaceuticals Inc (REGN) opened at $323.86 on Monday. Regeneron Pharmaceuticals Inc has a one year low of $313.53 and a one year high of $543.55. The stock has a market cap of $34,800.00, a price-to-earnings ratio of 24.65, a P/E/G ratio of 1.02 and a beta of 1.47. The company has a quick ratio of 3.18, a current ratio of 3.82 and a debt-to-equity ratio of 0.11.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported $5.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.18 by $1.05. Regeneron Pharmaceuticals had a net margin of 20.41% and a return on equity of 28.48%. The firm had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.50 billion. During the same quarter last year, the company earned $3.04 EPS. The firm’s revenue for the quarter was up 28.9% compared to the same quarter last year. equities analysts expect that Regeneron Pharmaceuticals Inc will post 19.2 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece was first published by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at https://www.tickerreport.com/banking-finance/3222710/regeneron-pharmaceuticals-inc-regn-shares-sold-by-bbva-compass-bancshares-inc.html.
Regeneron Pharmaceuticals Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.